PRTO Fundamental Analysis - Proteon Therapeutics Inc.

No Fundamental Analysis report for PRTO not available.

Proteon Therapeutics Inc.

NASDAQ:PRTO (1/9/2020, 8:26:19 PM)

After market: 0.712 -0.12 (-14.75%)

0.8352

+0.19 (+28.45%)

Chartmill FA Rating

GICS SectorN/A

GICS IndustryGroupN/A

GICS IndustryN/A

Earnings (Last)N/A N/A

Earnings (Next)N/A N/A

Inst Owners23.03%

Inst Owner Change-18.28%

Ins Owners31.18%

Ins Owner Change0%

Market Cap18.52M

Revenue(TTM)N/A

Net Income(TTM)-18.64M

Analysts73.4

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly Dividend0

Dividend Growth(5Y)0%

DP0%

Div Incr YearsN/A

Div Non Decr YearsN/A

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	2.31
P/tB	N/A
EV/EBITDA	-0.36

EPS(TTM)-0.96

EYN/A

EPS(NY)-0.34

Fwd EYN/A

FCF(TTM)N/A

FCFYN/A

OCF(TTM)N/A

OCFYN/A

SpS0

BVpS0.36

TBVpSN/A

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-193.21%
ROE	N/A
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3Y0%

ROICexgc growth 5Y0%

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score3

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	5.98
Quick Ratio	5.98
Altman-Z	-30.97

F-Score3

WACCN/A

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)18.64%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%68%

EPS Next Y32.17%

EPS Next 2Y44.29%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1YN/A

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1YN/A

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1YN/A

OCF growth 3YN/A

OCF growth 5YN/A

Proteon Therapeutics Inc. / PRTO FAQ

What is the ChartMill fundamental rating of Proteon Therapeutics Inc. (PRTO) stock?

ChartMill assigns a fundamental rating of 3 / 10 to PRTO.

What is the valuation status for PRTO stock?

ChartMill assigns a valuation rating of 2 / 10 to Proteon Therapeutics Inc. (PRTO). This can be considered as Overvalued.

How profitable is Proteon Therapeutics Inc. (PRTO) stock?

Proteon Therapeutics Inc. (PRTO) has a profitability rating of 1 / 10.

How financially healthy is Proteon Therapeutics Inc.?

The financial health rating of Proteon Therapeutics Inc. (PRTO) is 4 / 10.

What is the expected EPS growth for Proteon Therapeutics Inc. (PRTO) stock?

The Earnings per Share (EPS) of Proteon Therapeutics Inc. (PRTO) is expected to grow by 32.17% in the next year.

Proteon Therapeutics Inc. (PRTO) Stock Fundamental Analysis